Showing 161 - 180 results of 298 for search '"breast"', query time: 0.09s Refine Results
  1. 161
  2. 162

    An App-Based Intervention With Behavioral Support to Promote Brisk Walking in People Diagnosed With Breast, Prostate, or Colorectal Cancer (APPROACH): Process Evaluation Study by Fiona Kennedy, Susan Smith, Rebecca J Beeken, Caroline Buck, Sarah Williams, Charlene Martin, Phillippa Lally, Abi Fisher

    Published 2025-02-01
    “…MethodsAdults (aged ≥18 y) with breast, prostate, or colorectal cancer who reported not meeting the UK guidelines for moderate-to-vigorous physical activity (≥150 min/wk) were recruited from a single hospital site in Yorkshire, United Kingdom. …”
    Get full text
    Article
  3. 163
  4. 164

    Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota by Min Yang, Jia Guo, Jinxian Li, Shuyue Wang, Yuan Sun, Ying Liu, Yinghua Peng

    Published 2025-02-01
    “…Abstract Despite the approval of several artificial nanotherapeutics for the treatment of triple-negative breast cancer (TNBC), significant challenges, including unsatisfactory therapeutic outcomes, severe side effects, and the high cost of large-scale production, still restrict their long-term application. …”
    Get full text
    Article
  5. 165

    Antioxidant activity of Micractinium sp. (Chlorophyta) extracts against H2O2 induced oxidative stress in human breast adenocarcinoma cells by Onur Bulut, Işkın Engin Köse, Çağla Sönmez, Hüseyin Avni Öktem

    Published 2024-11-01
    “…Moreover, extracts from Micractinium sp. exhibited remarkable cytoprotective activity by effectively inhibiting hydrogen peroxide-induced oxidative stress and cell death in human breast adenocarcinoma (MCF-7) cells. In conclusion, with its diverse biochemical composition and adaptability to different growth regimens, Micractinium sp. emerges as a robust candidate for mass cultivation in nutraceutical and food applications.…”
    Get full text
    Article
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173

    The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis by Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

    Published 2021-06-01
    “…**Methods:** This was a retrospective observational study in patients with breast cancer (BC) who received myelosuppressive chemotherapy and prophylactic pegfilgrastim identified January 1, 2017-May 31, 2018 from MarketScan® research databases. …”
    Get full text
    Article
  14. 174

    Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data by David Weller, Usha Menon, Alina Zalounina Falborg, Henry Jensen, Andriana Barisic, Anne Kari Knudsen, David H Brewster, Victoria Cairnduff, Eva Grunfeld, Elizabeth Harland, Mats Lambe, Rebecca-Jane Law, Yulan Lin, Martin Malmberg, Donna Turner, Richard D Neal, Victoria White, Samantha Harrison, Peter Vedsted, Una MacLeod, Conan Donnelly, Anna Gavin, Jon Emery, Oliver Bucher, Jatinderpal Kalsi, Chantelle Anandan, Evangelia Ourania Fourkala, Therese Kearney, Marie-Louise Essink-Bot, Sigrun Saur Almberg, Breann Hawryluk, Jacqueline Kelly, Jackie Boylan, Jan Willem Coebergh, David Brewster, Stefan Bergström, Victoria Hammersley, Rebecca Bergin, Alina Zalounina Falborg, Andriana Barisi, Kerry Moore, Maria Rejmyr Davis

    Published 2022-12-01
    “…Objectives A growing body of evidence suggests longer time between symptom onset and start of treatment affects breast cancer prognosis. To explore this association, the International Cancer Benchmarking Partnership Module 4 examined differences in breast cancer diagnostic pathways in 10 jurisdictions across Australia, Canada, Denmark, Norway, Sweden and the UK.Setting Primary care in 10 jurisdictions.Participant Data were collated from 3471 women aged >40 diagnosed for the first time with breast cancer and surveyed between 2013 and 2015. …”
    Get full text
    Article
  15. 175

    Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

    Published 2025-02-01
    “…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. …”
    Get full text
    Article
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180